130 related articles for article (PubMed ID: 30659513)
1. Patient and Oncologist Preferences for the Treatment of Adults with Advanced Soft Tissue Sarcoma: A Discrete Choice Experiment.
Ivanova J; Hess LM; Garcia-Horton V; Graham S; Liu X; Zhu Y; Nicol S
Patient; 2019 Aug; 12(4):393-404. PubMed ID: 30659513
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of treatment patterns among recurrent/metastatic soft tissue sarcoma patients who consulted medical oncologists in Japan.
Nakano K; Ae K; Matsumoto S; Takahashi S
J Orthop Sci; 2019 Nov; 24(6):1081-1087. PubMed ID: 31447093
[TBL] [Abstract][Full Text] [Related]
3. Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries.
de Freitas HM; Ito T; Hadi M; Al-Jassar G; Henry-Szatkowski M; Nafees B; Lloyd AJ
Adv Ther; 2019 Feb; 36(2):318-332. PubMed ID: 30617763
[TBL] [Abstract][Full Text] [Related]
4. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Shinde R; Basurto E; Joseph RW
Patient Prefer Adherence; 2017; 11():1389-1399. PubMed ID: 28860722
[TBL] [Abstract][Full Text] [Related]
5. Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany.
Hofheinz R; Clouth J; Borchardt-Wagner J; Wagner U; Weidling E; Jen MH; Brück P
BMC Cancer; 2016 Dec; 16(1):937. PubMed ID: 27923357
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.
Verschoor AJ; Litière S; Marréaud S; Judson I; Toulmonde M; Wardelmann E; van der Graaf WT; Le Cesne A; Gronchi A; Gelderblom H
Eur J Cancer; 2018 May; 94():187-198. PubMed ID: 29574364
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
Chugh R; Dunn R; Zalupski MM; Biermann JS; Sondak VK; Mace JR; Leu KM; Chandler WF; Baker LH
J Clin Oncol; 2005 May; 23(15):3597-604. PubMed ID: 15908670
[TBL] [Abstract][Full Text] [Related]
8. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
Bottomley C; Lloyd A; Bennett G; Adlard N
J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
[TBL] [Abstract][Full Text] [Related]
9. Patient preferences for clinical follow-up after primary treatment for soft tissue sarcoma: a cross-sectional survey and discrete choice experiment.
Damery S; Biswas M; Billingham L; Barton P; Al-Janabi H; Grimer R
Eur J Surg Oncol; 2014 Dec; 40(12):1655-61. PubMed ID: 25108811
[TBL] [Abstract][Full Text] [Related]
10. Shared decision making about palliative chemotherapy: A qualitative observation of talk about patients' preferences.
Henselmans I; Van Laarhoven HW; Van der Vloodt J; De Haes HC; Smets EM
Palliat Med; 2017 Jul; 31(7):625-633. PubMed ID: 28618897
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Bailey HH; Mahoney MR; Ettinger DS; Maples WJ; Fracasso PM; Traynor AM; Erlichman C; Okuno SH
Cancer; 2006 Nov; 107(10):2462-7. PubMed ID: 17058289
[TBL] [Abstract][Full Text] [Related]
12. The Stability of Treatment Preferences Among Patients With Advanced Cancer.
Jabbarian LJ; Maciejewski RC; Maciejewski PK; Rietjens JAC; Korfage IJ; van der Heide A; van Delden JJM; Prigerson HG
J Pain Symptom Manage; 2019 Jun; 57(6):1071-1079.e1. PubMed ID: 30794935
[TBL] [Abstract][Full Text] [Related]
13. Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives.
Amin S; Tolaney SM; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Mulvihill E; Shinde R; McLaurin K
Future Oncol; 2022 May; 18(16):1927-1941. PubMed ID: 35249366
[TBL] [Abstract][Full Text] [Related]
14. Influence of physician specialty on treatment recommendations in the multidisciplinary management of soft tissue sarcoma of the extremities.
Wasif N; Smith CA; Tamurian RM; Christensen SD; Monjazeb AM; Martinez SR; Canter RJ
JAMA Surg; 2013 Jul; 148(7):632-9. PubMed ID: 23552630
[TBL] [Abstract][Full Text] [Related]
15. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
[TBL] [Abstract][Full Text] [Related]
16. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
[TBL] [Abstract][Full Text] [Related]
17. Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.
Fernández O; Lázaro-Quintela M; Crespo G; Soto de Prado D; Pinto Á; Basterretxea L; Gómez de Liaño A; Etxaniz O; Blasco S; Gabás-Rivera C; Aceituno S; Palomar V; Polanco-Sánchez C
Front Oncol; 2021; 11():773366. PubMed ID: 35070976
[TBL] [Abstract][Full Text] [Related]
18. How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China.
Zhang M; He X; Wu J; Wang X; Jiang Q; Xie F
Value Health; 2022 Oct; 25(10):1768-1777. PubMed ID: 35710892
[TBL] [Abstract][Full Text] [Related]
19. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
20. Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
Maculaitis MC; Liu X; Will O; Hanson M; McRoy L; Berk A; Crastnopol M
Patient Prefer Adherence; 2020; 14():2201-2214. PubMed ID: 33177814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
